Gene variants point to a potential cause of age-related macular degeneration
April 8th 2023According to National Eye Institute researchers, the variants generate malformed proteins that alter the stability of the membrane attack complex, which may drive a chronic inflammatory response in the retina.
Read More
Report: Physician payments should be tied to inflation-based index
March 16th 2023To support congressional action, 135 health organizations – including the American Academy of Ophthalmology – sent a letter to congressional leaders pointing out that a full inflation-based update is the primary solution to the ongoing problem with the Medicare Physician Fee Schedule.
Read More
UF Health researchers’ gene therapy for retina disorder shows promise in early testing
March 14th 2023According to a University of Florida Health, the researchers used gene therapy to both knock down and replace malfunctioning genetic material that affects light-sensing photoreceptors in the retina.
Read More
ONL Therapeutics gets funding to move lead compound into Phase 2 clinical trial
March 13th 2023According to the company, the funding supports the Phase 2 clinical study of ONL1204 ophthalmic solution to evaluate the safety and efficacy in patients diagnosed with macula-off rhegmatogenous retinal detachment.
Read More
Iveric Bio releases data in geographic atrophy from avacincaptad pegol GATHER trials
March 9th 2023According to the company, post-hoc time-to-event analysis signals up to 59% risk reduction in rate of vision loss compared to sham treatment at 12 months. The analysis will be presented at the ARVO Annual Meeting from April 23-27 in New Orleans.
Read More
Anti-properdin antibody demonstrates efficacy in a primate model of wet-AMD and dry-AMD
March 6th 2023The company’s therapeutic is a single therapy for multiple forms of age-related macular degeneration. NM3086 is a highly potent alternative pathway (AP) blocker that does not affect the classical pathway.
Read More